Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jiangsu Dasheng Group Diyi Pharmaceutical is a prominent Chinese pharmaceutical manufacturer based in the Lianyungang economic development zone. As a core subsidiary of the Jiangsu Dasheng Group (also known as TASUN Group), the company specializes in the large-scale production of active pharmaceutical ingredients (APIs) and finished dosage forms, including tablets, capsules, and granules. Its commercial portfolio is primarily focused on small molecule generics across therapeutic areas such as anti-infectives, cardiovascular health, and metabolic disorders. The company operates multiple GMP-certified facilities and maintains a significant presence in both the domestic Chinese market and international export markets. By leveraging integrated chemical synthesis capabilities, the firm provides cost-effective treatments for common chronic and acute conditions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Jiangsu TASUN Group Diyi Pharmaceutical.